CLRB · Cellectar Biosciences, Inc. · Fails to Deliver
$2.34
-0.07 (-2.90%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Market Cap
$22.78M
Shares
9.45M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-10 | 315 | $2.57 | $810 |
| 2026-08-03 | 32,868 | $2.57 | $84,471 |
| 2026-07-31 | 11,885 | $2.53 | $30,069 |
| 2026-07-30 | 25,403 | $2.48 | $62,999 |
| 2026-07-24 | 756 | $2.47 | $1,867 |
| 2026-07-21 | 403 | $2.52 | $1,016 |
| 2026-07-17 | 3,260 | $2.58 | $8,411 |
| 2026-07-16 | 3,306 | $2.61 | $8,629 |
| 2026-07-14 | 1,960 | $2.63 | $5,155 |
| 2026-07-13 | 5,147 | $2.82 | $14,515 |
| 2026-07-10 | 261 | $2.77 | $723 |
| 2026-07-07 | 1,894 | $2.77 | $5,246 |
| 2026-07-06 | 871 | $2.81 | $2,448 |
| 2026-07-02 | 6,018 | $2.83 | $17,031 |
| 2026-07-01 | 17,280 | $2.78 | $48,038 |
| 2026-06-30 | 1,204 | $2.60 | $3,130 |
| 2026-06-29 | 537 | $2.52 | $1,353 |
| 2026-06-24 | 192 | $2.50 | $480 |
| 2026-06-18 | 22,579 | $2.48 | $55,996 |
| 2026-06-17 | 22,424 | $2.45 | $54,939 |
| 2026-06-10 | 2,269 | $2.36 | $5,355 |
Showing 1–21 of 21 settlements
Key facts
CIK
1279704
CUSIP
15117F880
13F (30d)
23 filings
23 filers
Visit website
Investor relations